AbbVie (ABBV)
(Delayed Data from NYSE)
$195.45 USD
-1.37 (-0.70%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $195.38 -0.07 (-0.04%) 4:18 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$195.45 USD
-1.37 (-0.70%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $195.38 -0.07 (-0.04%) 4:18 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
The Zacks Analyst Blog Highlights: AbbVie, Starbucks, Phillips 66, Anheuser-Busch InBev and Square
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Starbucks, Phillips 66, Anheuser-Busch InBev and Square
Top Ranked Income Stocks to Buy for October 2nd
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, October 2nd.
Top Stock Reports for AbbVie, Starbucks & Phillips 66
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including AbbVie (ABBV), Starbucks (SBUX) and Phillips 66 (PSX).
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $75.73 in the latest trading session, marking a +1.18% move from the prior day.
Is AbbVie (ABBV) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
AbbVie (ABBV) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
AbbVie (ABBV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here is Why Growth Investors Should Buy AbbVie (ABBV) Now
by Zacks Equity Research
AbbVie (ABBV) could produce exceptional returns because of its solid growth attributes.
AbbVie (ABBV) Gets FDA Nod for Label Expansion of HCV Drug
by Zacks Equity Research
AbbVie (ABBV) gets FDA approval for the label expansion of Mavyret.
This is Why AbbVie (ABBV) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $72.97 in the latest trading session, marking a +0.8% move from the prior day.
AC Immune to Earn Milestone From Lilly for Alzheimer's Drug
by Zacks Equity Research
AC Immune (ACIU) will gain a milestone payment of CHF30 million from partner Eli Lilly for the initiation of the phase I study of ACI-3024, currently being developed to treat Alzheimer's disease.
The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, CSX, Danaher and ONEOK
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, CSX, Danaher and ONEOK
Top Analyst Reports for AbbVie, Union Pacific & CSX
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including AbbVie (ABBV), Union Pacific (UNP) and CSX (CSX).
Novartis Announces New Data on Spondylitis Drug Cosentyx
by Zacks Equity Research
Novartis (NVS) announces new positive data from a phase III study on Cosentyx in patients with active nr-axSpA.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $70.59, moving +0.11% from the previous trading session.
Dividend Growth ETFs for Long Term Investors
by Neena Mishra
Dividend growth ETFs hold companies with solid balance sheets and rising earnings.
Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland
by Zacks Equity Research
Vertex (VRTX) secures reimbursement nods in Scotland for its cystic fibrosis drugs Orkambi and Symkevi.
4 Big Drugmakers Boasting Impressive Oncology Pipelines
by Kinjel Shah
We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $66.70, moving -1.36% from the previous trading session.
The Zacks Analyst Blog Highlights: Microsoft, Home Depot, AbbVie, Disney and Host Hotels
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Home Depot, AbbVie, Disney and Host Hotels
Top Stock Reports for Microsoft, Home Depot & AbbVie
by Mark Vickery
Today's Research Daily features updated research reports on 16 major stocks, including Microsoft (MSFT), Home Depot (HD) and AbbVie (ABBV).
J&J's Stelara Gets Approval in EU for Ulcerative Colitis
by Zacks Equity Research
Johnson & Johnson (JNJ) receives European Commission's (EC) approval for the label expansion of Stelara for the treatment of adults with moderately-to-severely active ulcerative colitis (UC).
The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie
by Zacks Equity Research
The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie
AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails
by Zacks Equity Research
IDMC recommends termination of AbbVie's (ABBV) late-stage study on its small cell lung cancer candidate, Rova-T. AbbVie discontinues development.